Celgene-backed Nurix Therapeutics will use the capital to advance two protein modulation-based immuno-oncology drug candidates toward clinical trials.
Nurix Therapeutics, a US-based oncology drug developer that counts pharmaceutical firm Celgene as an investor, has completed a $120m round led by life sciences investment firm Foresite Capital.
Incubator and venture capital firm Third Rock Ventures also contributed to the round, as did private equity firm Bain Capital’s Life Sciences unit, Tavistock Group’s Boxer Capital, EcoR1 Capital, Redmile Group, Wellington Management, Column Group and an undisclosed investor.
Founded in 2009 as Kura Therapeutics, Nurix is developing cancer drugs that modulate…
